NCT02251483View on ClinicalTrials.gov

Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Diarrhea Predominant Irritable Bowel SyndromeSmall Intestinal Bacterial Overgrowth
Interventions
OTHER

Serum-derived bovine immunoglobulin protein isolate (SBI)

OTHER

Placebo

Trial Locations (1)

90048

GI Motility Program Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Entera Health, Inc
All Listed Sponsors
collaborator

Entera Health, Inc

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER

NCT02251483 - Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth | Biotech Hunter | Biotech Hunter